EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Elevations of Th17.1 Cells ( CXCR3 + CCR6 + T Cells With IL ‐ 17A and IFN ‐γ Production) in Peripheral Blood of Patients With Lung Cancer

Jiaoyun Lv, Wencheng Yin, Xialin Nie, Siyuan Chen, Yuqi Zhong, Shufa Yang, Ziyi He, Yanhong Yao, Qiqi Wang, Yang Zhao, Hui Dai

Immunology · 2026-12 · 179 (4) · 635-646

DOI: 10.1111/imm.70197 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Peripheral T cell profiles reflect antitumour immunity, yet systemic immune shifts often remain confounded by demographic factors. This study aimed to delineate true tumour‐driven T cell alterations in lung cancer. We analysed peripheral blood from 121 lung cancer patients and strictly age‐ and sex‐matched healthy controls using multiparametric flow cytometry, corroborated by human lung cancer spatial transcriptomics (ST). Following demographic standardisation, patients exhibited a systemic T cell priming blockade, characterised by significantly accumulated naïve T cells and depleted effector memory T cells (CD4 + p < 0.01; CD8 + p < 0.0001). Conversely, Th17.1 cells and immune checkpoints (e.g., PD‐1, CTLA‐4) were robustly elevated. Crucially, ST validated a striking intratumoural spatial accumulation of Th17.1 cells. We conclude that the peripheral expansion of Th17.1 cells is a genuine tumour‐driven event that faithfully mirrors local tumour microenvironment remodelling and potential Tertiary Lymphoid Structure (TLS) neogenesis. This positions peripheral Th17.1 profiling as a valuable, noninvasive biomarker for evaluating systemic immunosuppression and guiding personalised immunotherapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →